MMB dosing and hepcidin levels over time. (A) Individual intrapatient change in hepcidin levels at baseline (no MMB treatment) and at enrollment (first MMB dose). (B) Overall population hepcidin levels over time. (C) Hepcidin daily change (median of the individual changes in hepcidin from morning to 6 hours later per time point) in the overall population. (D) Hepcidin daily change (median of the individual changes in hepcidin from morning to 6 hours later per time point) in the TI-R and TI-NR subgroups. (E) Morning/predose hepcidin levels in TI-R and TI-NR subgroups relative to baseline. (F) Morning/predose hepcidin levels in the TI-R subgroup relative to pre–TI-R levels (pre–TI-R is the last visit with data before the start of TI response, week 2 is the visit 2 weeks after the pre-TI response visit; the same applies to the other post-TI response visits). In all panels, open symbols are predose, and filled symbols are 6 hours postdose.